Innovation Efficiency & Paradigm Shift in Drug Discovery Evotec Company Overview
|
|
- Cleopatra Copeland
- 6 years ago
- Views:
Transcription
1 Innovation Efficiency & Paradigm Shift in Drug Discovery Evotec Company Overview Evotec AG, Company Presentation, June 2017
2 Forward-looking statements Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. 1
3 Agenda Evotec Overview EVT Execute EVT Innovate Financials & Outlook 2
4 Unique discovery platform and business model Evotec at a glance State of play Profitable & Growing Strong financial performance m revenues (2016), 36.2 m adjusted EBITDA (2016) Strong balance sheet and good strategic position with m liquidity (Q1 2017) EVT Execute Leading innovation efficient drug discovery outsourcing platform Key alliances with leading Pharma companies, foundations and biotech companies for standalone services and integrated projects EVT Innovate Key scientific discovery expertise and platforms in five major disease areas Efficient approaches for participation in first-in-class innovation through BRIDGE from Academia to Pharma Strong platforms & pipeline > 70 co-owned preclinical and clinical candidates Equity participation in selected company formations Industry-leading ipsc 1) drug discovery platform > 1,000 scientists in EU & US 3 1) ipsc = induced pluripotent stem cells
5 Leading the macro trend in R&D productivity Market dynamics in drug discovery Key growth drivers Drug discovery outsourcing is a macro trend Market overview Revenues, in $ bn 1 2 Increasing comfort with outsourcing also in drug discovery Higher R&D capital efficiency through switch from fixed costs to variable business models % p.a Ability to adjust investments proportional to portfolio needs (e) 2018(e) 2019(e) 2020(e) 4 Source: Visiongain Drug Discovery Outsourcing Market Forecast
6 Long-term strategy to co-own products, achieve service revenues, milestones and royalties Strategy overview Restructuring Capital efficiency for sustainability First Cure X investments Business segmentation Investments in discovery service platform Performance-based integrated discovery and clinical alliances Cure X/Target X strategy Royalty income from legacy pipeline Highest quality drug discovery and pre-clinical services Cure X/Target X alliances & Academic BRIDGE strategy Company formations to accelerate drug discovery and product development 5
7 Integrated offering from IP to IND Our Sweet spot : The Pre-clinical Development Candidate ( PDC ) Academia Target ID/Validation Hit- Identification Lead Optimisation Preclinical Phase I Phase II Phase III Approval Market Clinical Phase Duration > 14 years Evotec Approx. 3 6 years PDC Pre-clinical development candidate Partner Approx years Cost Approx. $ 1 3 bn Approx. $ 5 15 m Evotec s core competencies 6 Source: Paul et al. Nature Reviews Drug Discovery, 9 (2010) IP = Intellectual Property IND = Investigational New Drug
8 Our offering close to Pharma, biotech and Academia Evotec s global footprint >1,200 employees, >1,000 scientists in EU & US Princeton, Branford, Watertown and San Francisco, USA ~110 employees Compound ID, selection and acquisition Compound QC, storage and distribution Cell & protein production ADME-Tox, DMPK Abingdon, Manchester/ Alderley Park, UK ~400 employees Medicinal chemistry ADME-Tox, DMPK Structural biology In vitro & in vivo anti-infective platform/screening Toulouse, France ~300 employees Compound management Hit identification In vitro & in vivo oncology Medicinal chemistry ADME & PK Early drug formulation & Solid form screening Cell, protein & antibody production Hamburg (HQ), Göttingen and Munich, Germany ~430 employees Hit identification In vitro & in vivo biology Chemical proteomics & Biomarker discovery and validation Cell & protein production Antibody discovery 7
9 ONE high-quality discovery platform EVT Execute & EVT Innovate Business model 8
10 Agenda Evotec Overview EVT Execute EVT Innovate Financials & Outlook 9
11 No 1 in drug discovery outsourcing services Service offering overview 10
12 Strong growth in EVT Execute EVT Execute Key performance indicators Q Revenues 1) (in m) Intersegment revenues % Adjusted EBITDA 2) (in m) % 12.2 Increase in EVT Execute revenues attributable to growth in the base business and three months Cyprotex contribution In the first quarter of 2017, Cyprotex contributed revenues of 6.0 m Significant upswing of adjusted EBITDA mainly due to the strong growth in revenues at higher gross margin Q Q Q Q Q Q ) Including intersegment revenues 2) Before contingent considerations, income from bargain purchase and excluding impairments on goodwill, other intangible and tangible assets as well as the total nonoperating result
13 Well balanced customer mix EVT Execute Selected customer and revenue metrics Revenues by customer segment ytd ) (in %) Customer type ytd ) (in %) Revenues by region ytd ) (in %) Remaining Top Customers 15% 19% 100% Mid-sized Pharma Foundations 9% 13% 100% ROW 2% 100% USA 43% Biotech 35% Top 10 Long-term Strategic Alliances 66% Top 20 Pharma 44% Europe 55% 12 1) Third-party revenues only
14 Cyprotex successful integration Cyprotex Initial achievements & outlook Summary of Transaction 1) Acquisition completed in December 2016 Cyprotex delisted from AIM Final payment of 66.3 m in cash for acquisition and funding of company debt Revenues 2016: GBP 18.8 m EBITDA 2016: GBP 3.1 m Organisation, leadership and systems integration Strong leadership team in place Relocation of UK operations from Macclesfield to Alderley Park completed in Jan 2017 Cyprotex continues to operate and serve its client base in all segments under the brand Cyprotex An Evotec company New business and further opportunities on horizon Very good integration in complete Evotec offering Revenues Q1 2017: 6.0 m Large, strategic contract with major Pharma company signed in Q Approx. 20 m revenues expected in ) Full-year 2016 Cyprotex numbers. Evotec is only eligible for consolidating the last two weeks of 2016 Cyprotex business
15 Trusted partner of foundations Foundations & Evotec Indication (mechanism) Partner Timeline Antibiotic resistance Parkinson s Disease Huntington s Disease Antibiotic Research UK Michael J. Fox Foundation CHDI Foundation Start 2016 Start 2016 Start 2006, extended through to 2018 Disease foundations are increasingly driving science and they are turning to companies like Evotec to pursue novel drug discovery pathways 1) Juvenile Batten Disease Beyond Batten Disease Foundation Start 2015 Muscular dystrophies Jain Foundation Start 2013 Malaria Medicines for Malaria Venture Start ) Over 6,000 rare disease NGOs; more than 10,000 relevant private foundations with more than $ 5 bn funding
16 A good start into the year and a strong outlook EVT Execute Expected key milestones 2017 New long-term deals with large and mid-sized Pharma New performance-based integrated technology/disease alliance Expansion of foundations and biotech network in USA/Europe Milestones from existing alliances 15
17 Agenda Evotec Overview EVT Execute EVT Innovate Financials & Outlook 16
18 Five fields of core expertise with major market need EVT Innovate Overview NEURONAL DISEASES Market potential > 500 bn DIABETES & COMPLICATIONS Market potential > 500 bn PAIN Market potential > 50 bn ONCOLOGY Market potential > 150 bn ANTI- INFECTIVES Market potential > 30 bn 17 Source: IMS Institute for Healthcare Informatics; IDF Atlas 2015; Grand View Research; Transparency Market Research; Annals of Neurology
19 Revenue growth reflects partnering of R&D projects EVT Innovate Key performance indicators Q Revenues (in m) Adjusted EBITDA 1) (in m) R&D expenses (in m) +96% % (3.8) (2.4) Q Q Q Q Q Q Q Q Q Revenue growth of 96% and improved adjusted EBITDA resulting from new partnership with Celgene signed in 2016 as well as milestone achievements Increased R&D expenses due to intensified efforts in metabolic diseases and oncology 18 1) Before contingent considerations, income from bargain purchase and excluding impairments on goodwill, other intangible and tangible assets as well as the total nonoperating result
20 Discovery Pre-clinical Clinical > 70 co-owned product opportunities and growing Partnership portfolio Molecule Therapeutic Area/Indication Partner Discovery Pre-clinical Phase I Phase II Phase III EVT302 1) CNS Alzheimer s disease EVT201 CNS Insomnia EVT100 1) CNS Depression EVT401 Immunology & Inflammation ND 2) ND 2) Various ND 2) ND 2) ND 2) Oncology Oncology Women s health Endometriosis CNS Pain Immunology & Inflammation Oncology EVT770 Metabolic Diabetes (type 2/1) ND 2) ND 2) Various EVT801 EVT701 EVT601 ND 2) Various Respiratory Immunology & Inflammation Women s health Endometriosis Oncology Oncology Oncology Nephrology NEW - Key milestones achieved Immunology & Inflammation Various Metabolic Diabetes (type 2/1) Various Metabolic Diabetes (type 2/1) Various Nephrology Various Metabolic Diabetes NEW - Key milestone achieved Various Oncology Immunotherapy Various Immunology & Inflammation Tissue fibrosis Various Neurodegeneration Various Metabolic Diabetes >5 further programmes Various CNS >5 further programmes Various Oncology >10 further programmes Various CNS Pain & Inflammation >5 further programmes 19 1) EVT302 and EVT100: Partner stopped development; Evotec has regained the licence rights (EVT100 series: Patents have been discontinued in 2016) 2) Not disclosed
21 First-in-class alliances with significant upside Key innovation alliances Selection Chronic kidney disease ( CKD ) Highly innovative therapeutics in diabetic complications (e.g. CKD) Immuno-oncology Development of small molecule based cancer immunotherapies to complement current offerings of checkpoint inhibitors (together with Apeiron Biologics) Commercials 1) Undisclosed upfront payment, potential milestones > 300 m, double-digit royalties Commercials 1) Substantial research payments, potential milestones > 200 m, double-digit royalties Fibrosis Novel mechanisms as targeted anti-fibrotics in multi-organ fibrosis Commercials 1) Undisclosed upfront payment, potential milestones > 100 m Endometriosis/Pain World-leading efforts in non-hormonal treatments in endometriosis Commercials 2) 12 m upfront, potential milestones > 500 m, double-digit royalties 20 1) Recognised in EVT Innovate 2) Recognised in EVT Execute
22 Clear strategy towards global leadership in induced pluripotent stem cells (ipsc) From scientific discovery to strategy Initiation of ipsc 1) platform CureMN (ALS 2) / neurodegeneration) >10 scientists Collaboration with e.g. Broadening of pipeline and first strategic deals Build > 50 scientists and leadership team Strategic alliance in diabetes Strategic alliance in neurodegeneration Outlook Strategic platform development into other disease areas New partnerships Feed clinical stage pipeline together with our partners >100 scientists Key network with: 21 1) ipsc = induced pluripotent stem cells 2) ALS = Amyotrophic lateral sclerosis
23 ipsc alliances represent paradigm shift ipsc Alliances ipsc alliance in neurodegeneration Development of novel therapies for a broad range of neurodegenerative diseases based on Evotec s unique patient-derived ipsc platform Focus on ALS AD HD PD Commercials Amyotrophic lateral sclerosis Alzheimer s disease Huntington s disease Parkinson s disease. Upfront $ 45 m, potential milestones > $ 250 m per project, low double-digit royalties ipsc alliance in diabetes Development of beta cell replacement therapy and drug discovery based on functional human beta cells derived from Evotec s unique ipsc platform ipsc alliance in diabetes Beta cell replacement therapy Drug discovery Small molecules Commercials Upfront 3 m, research payments, potential milestones > 300 m, double-digit royalties 22
24 ipsc platform established over the last five years Key elements of drug discovery process with ipsc Screening Disease-specific drugs Disease in a dish Patient Patientspecific ipscs High-quality ipsc cultures at large scale (QC) Industrial processes for generation of patient-derived target cell types Robust disease-relevant phenotypic readouts for screening Panel of disease area focused patient-derived genotypes for patient stratification strategy 23 Figure modified from Nature Reviews Drug Discovery, Vol. 10, (2011)
25 ipsc technology shifts the drug discovery paradigm Advantages & hurdles with ipsc Drug discovery Cell therapy Key advantages Key hurdles Focus on human disease relevance already at screening stage Replacement of rodent cell & in vivo models Novel strategy for patient stratification In vitro clinical trials/precision medicine Novel translational biomarkers Excellent basis for more complex in vitro models Co-cultures/organoids Standardisation Industrialisation Autologous cell therapy can circumvent immune rejection In combination with gene editing technology provides potential cures Functional integration in tissues Regulatory challenges 24
26 Focus on human disease relevance from the start ipsc will shift the drug discovery paradigm Disease relevance OLD NEW with ipsc Key advantage In vitro models for drug screening/profiling Low High Patient-derived disease models for drug screening and profiling confers disease relevance early on In vivo models for drug screening/profiling Low High Efficacy testing in animal models focus more on MoA 1) and PK/PD 2) profiles Pre-clinical patient stratification Not possible Possible Early patient stratification enables better focused clinical development Success rate in clinical testing even in well defined patient populations Low High With increased success rates, cost for development of and prices for medication will decrease 25 1) MoA = Mode of Action 2) PK/PD = Pharmacokinetic/Pharmacodynamic
27 Clinical trial in a dish will become reality Patient-derived ipsc lines available for multiple genotypes (e.g. ALS) 26
28 Various opportunities beyond neurodegeneration and diabetes Initial focus on genetically defined subpopulations Status Partnered Therapeutic area Neurodegenerative diseases, e.g. Amyotrophic lateral sclerosis Frontotemporal dementia Parkinson s disease Alzheimer s disease Huntington s disease Diabetes Drug discovery Cell therapy Unpartnered Lysosomal storage diseases Gaucher Fabry Batten MLIV 1) Myopathies FSHD 2) Duchenne Retinopathy Neurodevelopmental diseases Autism (Fragile X, Angelman, Shank3, TSC1/2) Spinal muscular atrophy Bipolar disorders. 27 1) MLIV = Mucolipidosis Type IV 2) FSHD = Facioscapulohumeral Muscular Dystrophy
29 Academic network continues to grow From Academia to transformative projects More than 30 partnerships 28
30 BRIDGE across the valley of death in drug discovery The Evotec BRIDGE Basic Research Applied Research Technology Development & Demonstration Product Commercialisation & Market Development Market Entry & Market Volume Sponsored Research Public Private Consortia Public Market Funding Level Pension Plan Governments Funding Gap Incubator Funds Project Finance Banks/Credit Lines Industry Acquisition Industry R&D Angel Investors Corporate Venture Capital Venture Capital/Private Equity 29 Source: Derived from an article by Sustainable Development Technology Canada (2013)
31 Upside participation in first-in-class innovation Strategic rationale & examples for Evotec s innovation acceleration Accelerating innovation on EVT platform Spin off valuable platforms outside of Evotec s main areas of interest for potential broader/later stage applications Participate in financing rounds of promising companies, built on Evotec s platforms, via strategic investments Company formations with the aim of developing assets to next value inflection points Panion Ltd 30
32 Improved human genetics enable better translation NURTuRE Consortium Biobanks in Nephropathy (Stiftung) Study centres Access to patient data & Sample material Unique patient sample collection: 3,000 patients with chronic kidney disease 1,000 patients with nephrotic syndrome High-quality patient material and systematic analysis for our goal: Identification of disease-causing mechanisms Expansion of drug discovery in kidney diseases Improving patient stratification Access to patient data 31
33 Strong outlook EVT Innovate Expected key milestones 2017 New clinical initiations and good progress of clinical pipeline within partnerships Expansion of academic BRIDGE network Strong R&D progress within Cure X/Target X initiatives Strong focus on ipsc (induced pluripotent stem cells) platform 32
34 Agenda Evotec Overview EVT Execute EVT Innovate Financials & Outlook 33
35 Continued strong performance Financial history (e) Overview Selected KPIs 1) Total Group revenues (in m) R&D expenses (in m) 2) (e) (e) Adjusted Group EBITDA (in m) Gross margin (in %) 2) (e) (e) 34 1) Including Cyprotex for 2017 (e) 2) Change in presentation for all 5 years: Amortisation reclassed to Costs of revenue and only in 2013 and 2014 to Research & development expenses
36 Growth driven by core business and milestones Condensed income statement Q Evotec AG and subsidiaries in m* Q Q % vs 2016 Revenues % Gross margin 37.4% 33.3% R&D expenses (4.7) (4.4) 6% SG&A expenses (7.3) (5.4) 36% Impairment of intangible assets - (1.4) - Other op. income (expenses), net % Operating income % Adjusted Group EBITDA 1) % Net income (loss) 6.9 (1.2) Group revenue growth due to increase in base revenues, milestones and contribution from Cyprotex ( 6.0 m) Gross margin mainly increased due to higher milestone payments SG&A increased due to Cyprotex and increased headcount from Company growth Other operating income increased due to R&D tax credits in France ( 1.2 m increase) 35 1) Before contingent considerations, income from bargain purchase and excluding impairments on goodwill, other intangible and tangible assets as well as the total nonoperating result * Differences may occur due to rounding
37 Adjusted EBITDA continues to grow Segment information Q Evotec AG and subsidiaries in m* EVT Execute EVT Innovate Intersegment elimination Evotec Group Revenues (10.3) 50.2 Gross margin 27.1% 56.9% 37.4% R&D expenses (0.2) (5.8) 1.3 (4.7) SG&A expenses (5.8) (1.5) - (7.3) Other op. income (expenses), net Operating income (loss) Adjusted EBITDA 1) Revenue growth in EVT Execute due to strong base business and three months 2017 contribution from Cyprotex Significantly improved revenues in EVT Innovate due to milestone achievements Higher SG&A in EVT Execute due to expenses of Cyprotex including its move in UK 36 1) Before contingent considerations, income from bargain purchase and excluding impairments on goodwill, other intangible and tangible assets as well as the total nonoperating result * Differences may occur due to rounding
38 Critical mass with highly skilled and experienced people Overview Human Resources Highly skilled workforce Scientists >1,200 employees, >1,000 scientists in EU & US >80% of all employees have an academic qualification >1,000 On average 8.5 years of experience in drug discovery per individual >50% of employees are women (e) >40 nationalities Approx. 50% of the employees have worked for the Company for more than five years 37
39 Strong team and shareholders for innovation Management & shareholder structure 10% Novo Holdings A/S 1) ~13.0% 67% Free float 9% Roland Oetker/ROI 5% AGI 2) 3% DAMI 3) 3% JPM 4) 1% Management Number of shares: m Listing: Frankfurt Stock Exchange (TecDAX), OTCBB 52 week high/low: 14.53/ 3.61 Management Board Werner Lanthaler (CEO) Long-time experience in Pharma & biotech Enno Spillner (CFO) Long-time experience in finance & biotech Mario Polywka (COO) Strong operational and commercial management track record Cord Dohrmann (CSO) Long-time experience in drug discovery and business development Supervisory Board Wolfgang Plischke Ex-Bayer Bernd Hirsch Bertelsmann SE & Co. KGaA Claus Braestrup Ex-Lundbeck Iris Löw-Friedrich UCB Michael Shalmi Novo Holdings A/S 1) Elaine Sullivan Carrick Therapeutics 38 1) Previously Novo A/S 2) Allianz Global Investors GmbH 3) Deutsche Asset Management Investment GmbH 4) J.P. Morgan Investment Management Inc., JPMorgan Chase Bank, National Association, JPMorgan Asset Management (UK) Limited
40 Strong growth and accelerated innovation Guidance ) 1 Doubledigit topline growth More than 15% Group revenue growth 1) 2 Profitable and growing Adjusted Group EBITDA 2) expected to improve significantly compared to Focused investments Group R&D expenses of approx. 20 m 39 1) Revenue guidance from 2017 onwards will be based on total Group revenues and no longer on revenues excluding milestones, upfronts and licences. Due to an increasing number of milestonebearing projects and factoring in a probability of success, total milestone-based revenues become more predictable and contribute more and more to the Company s total revenue and profitability. 2) Before contingent considerations, income from bargain purchase and excluding impairments on goodwill, other intangible and tangible assets as well as the total non-operating result
41 A strong 2017 ahead Expected key milestones 2017 New long-term deals with large and mid-sized Pharma New clinical initiations and good progress of clinical pipeline within partnerships New performance-based integrated technology/disease alliance Expansion of academic BRIDGE network Expansion of foundations and biotech network in USA/Europe Strong R&D progress within Cure X/ Target X initiatives Milestones from existing alliances Strong focus on ipsc (induced pluripotent stem cells) platform 40
42 Your contact: Dr Werner Lanthaler Chief Executive Officer +49.(0) (0) Fax
Evotec Leading external innovation
Evotec Leading external innovation Evotec AG, Company Presentation, Bank of America Merrill Lynch Global Healthcare Conference 2018, London, 13 September 2018 Forward-looking statement Information set
More informationEvotec Leading external innovation
Evotec Leading external innovation Evotec AG, Company Presentation, July 2018 Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve a number
More informationEvotec Leading external innovation
Evotec Leading external innovation Evotec AG, Company Presentation, June 2018 Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve a number
More informationEvotec Leading external innovation
Evotec Leading external innovation Evotec AG, Company Presentation, July 2018 Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve a number
More informationEvotec Leading external innovation
Evotec Leading external innovation Evotec AG, Company Presentation, September 2018 Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve
More informationEvotec Leading external innovation
Evotec Leading external innovation Evotec AG, Company Presentation, May 2018 Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve a number
More informationEvotec Leading external innovation
Evotec Leading external innovation Evotec AG, Company Presentation, April 2018 Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve a
More informationEvotec Leading external innovation
Evotec Leading external innovation Evotec AG, Company Presentation, Jefferies Healthcare Conference 2018, New York, 05 June 2018 Forward-looking statement Information set forth in this presentation contains
More informationEvotec Leading external innovation
Evotec Leading external innovation Evotec AG, Company Presentation, October 2018 Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve
More informationEvotec Leading external innovation
Evotec Leading external innovation Evotec AG, Company Presentation, October 2018 Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve
More informationEvotec Leading external innovation
Evotec Leading external innovation Evotec AG, Company Presentation, December 2018 Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve
More informationEvotec Leading external innovation
Evotec Leading external innovation Evotec AG, Company Presentation, November 2018 Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve
More informationEvotec Leading external innovation. Evotec AG, Company Presentation, Cantor Global Healthcare Conference, New York, 02 October 2018
Evotec Leading external innovation Evotec AG, Company Presentation, Cantor Global Healthcare Conference, New York, 02 October 2018 Forward-looking statement Information set forth in this presentation contains
More informationEvotec Leading external innovation
Evotec Leading external innovation Evotec AG, Company Presentation, January 2019 Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve
More informationGood start for external innovation with new business mix
Good start for external innovation with new business mix Evotec AG, First Quarter 2018 Results, 09 May 2018 Forward-looking statement Information set forth in this presentation contains forward-looking
More informationLeading external innovation Expansion of innovation
Leading external innovation Expansion of innovation Evotec AG, Nine-month 2017 Quarterly Statement, 08 November 2017 Forward-looking statements Information set forth in this presentation contains forward-looking
More informationEvotec = External Innovation Strong H1 2018
Evotec = External Innovation Strong H1 2018 Evotec AG, H1 2018 Interim Report, 09 August 2018 Forward-looking statement Information set forth in this presentation contains forward-looking statements, which
More informationEvotec. Partnered Drug Discovery and Development
Evotec Partnered Drug Discovery and Development Evotec AG, Company Presentation, January 2019 Forward-looking statement Information set forth in this presentation contains forward-looking statements, which
More informationEvotec. Partnered Drug Discovery and Development. Evotec AG, Company Presentation, 18th German Corporate Conference 2019, Frankfurt, 22 January 2019
Evotec Partnered Drug Discovery and Development Evotec AG, Company Presentation, 18th German Corporate Conference 2019, Frankfurt, 22 January 2019 Forward-looking statement Information set forth in this
More informationEVT Execute & EVT Innovate Profitable growth & First-in-class science
EVT Execute & EVT Innovate Profitable growth & First-in-class science Evotec AG, First Quarter 2016 Results, 10 May 2016 Forward-looking statements Information set forth in this presentation contains forward-looking
More informationLeading Innovation Efficiency Evotec Company Overview
Leading Innovation Efficiency Evotec Company Overview Evotec AG, Company presentation, November 2016 Forward-looking statements Information set forth in this presentation contains forward-looking statements,
More informationEVOTEC REPORTS FIRST QUARTER 2018 RESULTS AND PROVIDES CORPORATE UPDATE
, 09 MAY 2018 EVOTEC REPORTS FIRST QUARTER 2018 RESULTS AND PROVIDES CORPORATE UPDATE 55% INCREASE IN GROUP REVENUES STRONG UNDERLYING OPERATIONAL PERFORMANCE WITH NEW BUSINESS MIX AFTER APTUIT ACQUISITION
More informationLeading Innovation Efficiency Evotec Company Overview
Leading Innovation Efficiency Evotec Company Overview Evotec AG, Jefferies 2016 Global Healthcare Conference, 08 June 2016 Forward-looking statements Information set forth in this presentation contains
More informationEvotec & Sanofi enter into exclusive negotiations for major multi-component strategic collaboration
Evotec & Sanofi enter into exclusive negotiations for major multi-component strategic collaboration Evotec AG, Investor and Analyst Call, 03 December 2014 Forward-looking statements Information set forth
More informationEVOTEC AG FISCAL YEAR 2017 RESULTS: LEADING EXTERNAL INNOVATION
, 28 MARCH 2018 EVOTEC AG FISCAL YEAR 2017 RESULTS: LEADING EXTERNAL INNOVATION 57% INCREASE IN GROUP REVENUES, ADJUSTED GROUP EBITDA UP 60% EXPANSION OF LEADING EXTERNAL INNOVATION PLATFORM INTRODUCTION
More informationInnovation Efficiency - Company Overview
Innovation Efficiency - Company Overview Evotec AG, TVM Conference, Montreal, 7th October 2013 Research never stops Evotec Mission Together with our partners we are building a product pipeline based on
More informationAntibody Discovery at Evotec
Antibody Discovery at Evotec - Overview - Evotec Antibodies Adding value to our partners research Innovative and flexible solutions from target ID to pre-clinical candidate The people A wide therapeutic
More information14 May Evotec Q1 2013: Driving Innovation Efficiency
14 May 2013 Evotec Q1 2013: Driving Innovation Efficiency STRONG STRATEGIC POSITION SUPPORTS ACTION PLAN 2016 - INNOVATION EFFICIENCY EVOTEC S DRUG DISCOVERY PLATFORM GENERATES GROWTH NEW HORMONE IDENTIFIED
More informationBuilding innovative drug discovery alliances. Evotec 2014 Execute on Innovate
Building innovative drug discovery alliances Evotec 2014 Execute on Innovate Evotec AG, Full-Year Results 2013, 25 March 2014 Forward-looking statements Information set forth in this presentation contains
More information10 November Evotec reports nine months results: Upside materialising
10 November 2011 Evotec reports nine months results: Upside materialising - DISCOVERY ALLIANCE BUSINESS REPORTS PROFITABLE GROWTH WITH REVENUES UP 54% AND A POSITIVE OPERATING RESULT OF 9.5 M - STRONG
More informationEvotec AG, Full-Year Results 2011, Frankfurt, 20 th March Building innovative drug discovery alliances
Evotec AG, Full-Year Results 2011, Frankfurt, 20 th March 2012 Building innovative drug discovery alliances Forward-looking statements Information set forth in this presentation contains forward-looking
More informationBuilding innovative drug discovery alliances
Building innovative drug discovery alliances Q1 2011 Go for GROWTH Evotec AG, 1st Interim Report January March 2011, 12th May 2011 Forward-looking statements Information set forth in this presentation
More informationBuilding innovative drug discovery alliances. Evotec acquires Kinaxo
Building innovative drug discovery alliances Best in Class Drug Discovery - Evotec acquires Kinaxo Evotec AG Management, Munich / Hamburg, 10 th February 2011 Forward-looking statements Information set
More informationJefferies Global Health Care Conference. June 1, 2015
Jefferies Global Health Care Conference June 1, 2015 Forward-Looking Statements This presentation may contain projections, estimates and other forwardlooking statements that involve a number of risks and
More informationDrug Discovery insights. Building
DDin Drug Discovery insights Building Bridges TO ACCELERATE DRUG DISCOVERY The Valley of death Basic Research Applied Research Technology Development & Demonstration Product Commercialization & Market
More informationMarket Analysis & Segmentation. Gary Phillips CEO Bioshares 29 July 2016
Market Analysis & Segmentation Gary Phillips CEO Bioshares 29 July 2016 1 Forward looking statement This document contains forward looking statements, including statements concerning Pharmaxis future financial
More informationA full-service CRO with integrated early-stage capabilities
CHARLES RIVER TO ACQUIRE ARGENTA and BIOFOCUS A full-service CRO with integrated early-stage capabilities James C. Foster Chairman, President & CEO Thomas F. Ackerman Executive Vice President & CFO March
More informationCortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly
Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly May 14, 2015 Goteborg, Sweden and Trevose, Pa., USA and Victoria, Australia Cortendo AB (publ) [ticker: CORT
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT. For personal use only
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationDRUG DISCOVERY INSIGHTS EVOTEC AND CELGENE ENTER INTO DRUG DISCOVERY COL- LABORATION FOR NEURODEGENE- RATIVE DISEASES
DDin DRUG DISCOVERY INSIGHTS EVOTEC AND CELGENE ENTER INTO DRUG DISCOVERY COL- LABORATION FOR NEURODEGENE- RATIVE DISEASES Exclusive broad R&D collaboration based on Evotec s ipsc platform Mission Develop
More informationNew Expanded and Extended Strategic Collaboration with Biogen
New Expanded and Extended Strategic Collaboration with Biogen April 20, 2018 On Today s Call Stanley Crooke, M.D., Ph.D. Chief Executive Officer and Chairman Ionis Pharmaceuticals Beth Hougen Chief Financial
More informationValuing and Licensing Intellectual Property. Richard Williams
c Healthcare Valuing and Licensing Intellectual Property Richard Williams 9 May 2001 Agenda Exploitation of intellectual property The licence route- why and when? Choosing a partner Practical considerations
More informationCompany Report Daring to be different
Company Report 2010 Daring to be different Daring to be different Galapagos has continued to follow its own unique path and is now a leading international biotechnology company. In our 2010 report, we
More informationBY PEOPLE. WITH PEOPLE. FOR PEOPLE.
BY PEOPLE. WITH PEOPLE. FOR PEOPLE. :: 4SC AG, ENNO SPILLNER KORRELATION UNTERNEHMENSNACHRICHTEN & UNTERNEHMENSBEWERTUNG BERLIN, 19. MÄRZ 2013 FORWARD LOOKING STATEMENTS This presentation may contain projections
More informationBayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms
Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms Genomics Bioinformatics HTS Combinatorial chemistry Protein drugs
More informationCompany Profile. German-Taiwan Biotech Seminar 6 November 2017
Company Profile German-Taiwan Biotech Seminar 6 November 2017 Our Mission Bayer: Science For A Better Life A growing and aging world population requires an adequate supply of food and improved medical
More informationIdorsia Company Profile
Idorsia Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has
More informationProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011
ProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011 1 Forward Looking Statement / Copyright notice / Disclaimer Forward Looking Statement This presentation contains forward-looking
More informationBringing a successful partnership to the next level
Bringing a successful partnership to the next level Basle, 21 July 2008 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as
More informationJP Morgan Healthcare Conference January 9, 2012
JP Morgan Healthcare Conference January 9, 2012 SAFE HARBOR Certain statements in this presentation concerning our future growth prospects are forward-looking statements, which are subject to a number
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Michael Severino Vice Chairman and President January 9, 2019 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation are, or
More informationi-bodies a new class of protein therapeutics to treat human disease
i-bodies a new class of protein therapeutics to treat human disease AGM November 2016 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) s.cobb@adalta.com.au Disclaimer Investment in AdAlta is
More informationWhat IMI means for POLAND
What IMI means for POLAND Maciej Bagiński Gdansk University of Technology Deputy of Polish Delegate to IMI SRG History of calls 1 st call 15 projects (395 teams) 281 mln 2 nd call 8 projects (193 teams)
More informationAbout the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive
About the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive summary Licensing trends overview Evolving trends in the
More informationEuropean Induced Pluripotent Stem Cell Bank
European Induced Pluripotent Stem Cell Bank Background Researchers are looking for ways to validate pathways using human data. ips cells are one approach to this. ips research and banking is fragmented
More informationVertex and Moderna Establish Exclusive Collaboration to Discover and Develop mrna Therapeutics for Cystic Fibrosis
Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mrna Therapeutics for Cystic Fibrosis -Collaboration to explore use of mrna Therapeutics to treat the underlying cause of CF
More informationCheuvreux German Corporate Conference 2012
Cheuvreux German Corporate Conference 2012 Matthias Zachert Chief Financial Officer Frankfurt, January 17, 2012 Agenda 1 The Merck Group 2 Key strengths 3 Unlocking value 4 Financials 5 Summary 2 Merck
More informationImmuno-Oncology Program
Immuno-Oncology Program 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform
More information- PRESS RELEASE April 6 th, 2007 PRESS RELEASE April 6 th, PRESS RELEASE -
GENFIT S FINANCIAL RESULTS FOR 2006: PROFITABLE FOR THE 7 TH CONSECUTIVE YEAR DESPITE STRONGER INVESTMENT to the BENEFIT of the DRUG CANDIDATE PIPELINE - Profitable for the 7th consecutive year - Renewed
More informationAgios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationCourse Agenda. Day One
Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an
More informationModerna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 2016 Strategic Priorities
Moderna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 26 Strategic Priorities First Phase I study underway in Europe for mrna 44; IND for second program,
More informationCancer Research UK; $500m annual research spend on basic research, drug discovery and clinical development
Cancer Research UK; $500m annual research spend on basic research, drug discovery and clinical development Phil L Huillier Director Cancer Research Technology Ltd London, UK Who we are Cancer Research
More informationFacilitating Partnerships between Pharma and Academia
Facilitating Partnerships between Pharma and Academia Alan Lamont Director, SPBD Science and Technology Licensing 17 th February 2011 Opportunities for Commercialising Drug Discovery in the Academic Sector
More informationKPI Definition Comment Relates to Baseline Target
IMI2 Key performance indicators (KPIs) Reporting on measuring and outcomes on the ten following Key Performance Indicators will be provided yearly as part of the IMI2 JU Annual Activity Reports for year
More informationCommerzbank German Investment Seminar 2012
Commerzbank German Investment Seminar 2012 Matthias Zachert Chief Financial Officer New York, January 11, 2012 Agenda 1 The Merck Group 2 Key strengths 3 Unlocking value 4 Financials 5 Summary 2 Merck
More informationFinancial Results FY2018 Q3
Financial Results FY2018 Q3 (January to September 2018) Carna Biosciences, Inc. Stock Code:4572 1 FY2018 Q3 Key Highlights Established the clinical development team to initiate clinical trials of Carnaʼs
More informationGlobal leader in predictive diagnostics ASX: PIQ
Corporate Review Sydney Canary Capital 6 th June 2017 Global leader in predictive diagnostics ASX: PIQ 1 Business model Three synergistic business areas Unifying Promarker platform technology - leverage
More informationPhysiomics Plc. ("Physiomics" or "the Company") Interim Results Statement for the six month period ended 31 December 2015
The Magdalen Centre The Oxford Science Park Robert Robinson Avenue Oxford OX4 4GA UK Tel 01865 784980 Fax 08701 671931 ("Physiomics" or "the Company") Interim Results Statement for the six month period
More informationVISION & STRATEGY FIC LIC. Interview with the President
VISION & STRATEGY Interview with the President A conversation with Isao Teshirogi, President and CEO about the Shionogi Growth Strategy 2020 (SGS2020) VISION & STRATEGY SGS2020 Growth Strategies Under
More informationICON plc. 10th Jan Ciaran Murray CEO Steve Cutler CEO Designate. JP Morgan 35TH Annual Healthcare
ICON plc Ciaran Murray CEO Steve Cutler CEO Designate JP Morgan 35TH Annual Healthcare 10th Jan 2017 Forward Looking Statement Certain statements will be forward looking statements. Actual results may
More informationCONFLUENCE LIFE SCIENCES ACQUISITION
CONFLUENCE LIFE SCIENCES ACQUISITION Dr. Neal Walker President and CEO August 2017 Copyright 2017 Aclaris Therapeutics. All rights reserved. A-1 Disclaimer Any statements contained in this presentation
More informationFY18 Results Presentation 12 months to 30 June 2018
FY18 Results Presentation 12 months to 30 June 2018 Release date: 13 August 2018 2018 Cogstate Ltd. All rights reserved. 1 Investment Summary All results presented in US$ Continued growth in Clinical Trials
More informationleading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationA D V A N C I N G I N N O V A T I O N I N H E A L T H C A R E Partners Innovation Fund
A D V A N C I N G I N N O V A T I O N I N H E A L T H C A R E Partners Innovation Fund Partners HealthCare July 2017 P A R T N E R S I N N O V A T I O N F U N D In Brief Capitalization $165M fund $100
More informationBioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update
November 9, 2018 BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update NEW HAVEN, Conn., Nov. 09, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ( BTI ) (Nasdaq:
More informationOn Helix. 02 July Harren Jhoti President & CEO
On Helix 02 July 2014 Harren Jhoti President & CEO Astex Pharmaceuticals Global developer of small molecule drugs for unmet medical needs Expertise in oncology discovery & development World-class fragment-based
More informationInnovative Medicines Initiative - the story so far
Innovative Medicines Initiative - the story so far Ruxandra Draghia-Akli MD PhD Director Health, Research & DG Health Research at a Crossroads Are Public-Private Partnerships the Way Forward? European
More informationCapital Raising Presentation January 2017
Capital Raising Presentation January 2017 Disclaimer Some of the information in this presentation may refer to Dimerix Limited ( Dimerix or the Company ) based on information available to it as at the
More informationA GATEWAY TO ACADEMIC EXCELLENCE FOR BIOTECH AND PHARMA
A GATEWAY TO ACADEMIC EXCELLENCE FOR BIOTECH AND PHARMA Découpe 6 8 12 Connecting meaningful endpoints: Ksilink s comprehensive translational effort Ksilink s Patient centered, translational technology
More informationConsortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts
Consortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts Martha A. Brumfield, PhD President & CEO Agenda C-Path Model for Collaboration
More informationA Next Generation Stem Cell Therapeutics Company. Investor Presentation: Cynata Therapeutics Limited
A Next Generation Stem Cell Therapeutics Company Investor Presentation: Cynata Therapeutics Limited Important Information This presentation has been prepared by Cynata Therapeutics Limited. ( Cynata or
More informationFinancial Results FY2016
Financial Results FY2016 (January to December 2016) Carna Biosciences, Inc. Stock Code:4572 1 FY2016 Key Highlights Japan Patent Office granted a patent for CDC7/ASK inhibitor in January. Opened a research
More informationJ.P. MORGAN Healthcare Conference Robert Friel Chairman and CEO January 10, 2018
J.P. MORGAN Healthcare Conference Robert Friel Chairman and CEO January 10, 2018 Factors affecting future performance & non-gaap financial measures This presentation contains "forward-looking" statements
More informationSecond Quarter 2016 Financial Results. August 4, 2016
Second Quarter 2016 Financial Results August 4, 2016 Cautionary Note Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain forward-looking
More informationHORIZON DISCOVERY Joint Venture between Horizon Discovery & Centauri Therapeutics
HORIZON DISCOVERY Joint Venture between Horizon Discovery & Centauri Therapeutics Briefing 2 nd March 2016 Exec Summary Horizon Discovery Group plc Enters Immuno-Oncology Therapeutic Development and Forms
More informationMedivir Corporate Presentation December, A research-based pharmaceutical company focused on infectious diseases and oncology
Medivir Corporate Presentation December, 2015 A research-based pharmaceutical company focused on infectious diseases and oncology 2 Balanced platform of innovation and revenue generation Locations and
More informationProof of Concept. Achieve your molecule s full potential
Proof of Concept Achieve your molecule s full potential Table of contents 01 Maximize the value of your molecule 02 Enhance your resources and 03 Increase your speed and efficiency 04 your product s market
More informationINITIATOR PHARMA: HALF-YEAR REPORT 2017
INITIATOR PHARMA: HALF-YEAR REPORT 2017 Financial Highlights Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was
More informationFirst-in-Class Bispecific Antibodies For Cancer Immunotherapy
First-in-Class Bispecific Antibodies For Cancer Immunotherapy 2015 Company Highlights Vision Team Platform Pipeline Partners To dominate the bispecific antibody space in immunooncology through unique pipeline
More informationIMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager
IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager Introducing IMI2: Vienna 16 July 2014 The way in which pharmaceutical companies develop new medicines
More informationGood morning and thank you for joining us for our quarterly update.
Q1 2018 Earnings Conference Call May 7, 2018 11:00 AM ET Introduction and Forward Looking Statements in APPENDIX I Garo Armen Good morning and thank you for joining us for our quarterly update. We have
More informationJefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q
Jefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements
More informationDuncan Holmes European Head Discovery Partnerships with Academia GlaxoSmithKline
R&D Strategy Bridging g the academia-industry industry yg gap Duncan Holmes European Head Discovery Partnerships with Academia GlaxoSmithKline GSK at a glance Who we are We are a science-led global healthcare
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationInnovative Medicines Initiative
Innovative Medicines Initiative EMA - EBE Regulatory Conference on ATMPs Salah-Dine Chibout, Novartis Global Head Discovery & Investigative Safety/ Global Head Preclinical Safety Therapeutic Areas IMI
More informationLonza Capital Markets Day Staying Ahead. Marc Funk COO Lonza Pharma & Biotech. Capital Markets Day September 2018
Corporate Lonza Capital Markets Day 2018 Staying Ahead Marc Funk COO Lonza Pharma & Biotech Staying Ahead Lonza Capital Markets Day 2018 Agenda Outlook Lonza Pharma & Biotech overview Delivering on our
More informationAVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business Update
AVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business Update CAMBRIDGE, Mass. November 4, 2016 AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter
More informationThis presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform
This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements
More information